The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

As the Student Action Summit conference hosted by Charlie Kirk’s right-wing Turning Point USA group kicked off on Friday, ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...